Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 9/20 | 0.84 |
| ▸ | CACNA1D | Q01668 | 9/20 | 0.84 |
| ▸ | CACNA1S | Q13698 | 9/20 | 0.84 |
| ▸ | CACNA1C | Q13936 | 9/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | THPO | P40225 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11829739 | 0.98 | CACNA1F (0.88) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL11839673 | 0.96 | MEN1 (0.80) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL9765729 | 0.96 | CACNA1C (0.78) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL7282379 | 0.95 | CACNA1F (0.76) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL9765763 | 0.94 | MEN1 (0.82) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL11005401 | 0.94 | CACNA1F (0.74) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL6725228 | 0.94 | CACNA1F (0.87) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL11688627 | 0.93 | CACNA1F (0.90) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL10989784 | 0.93 | CACNA1C (0.72) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL7439297 | 0.92 | CACNA1F (0.72) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301370-A1 | COMBINATORY THERAPY FOR PREVENTING, INHIBITING, TREATING, OR REDUCING ANEURYSMS | The Regents of The University of California (US) | 2024-01-10 | — | — | EP | claimed |
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | INSPHERO AG (CH) | 2023-10-19 | — | — | US | claimed |
| EP-4225296-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | Insphero AG (CH) | 2023-08-16 | — | — | EP | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| WO-2022187349-A1 | COMBINATORY THERAPY FOR PREVENTING, INHIBITING, TREATING, OR REDUCING ANEURYSMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-09 | — | — | WO | claimed |
| WO-2022074057-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | INSPHERO AG (CH) | 2022-04-14 | — | — | WO | claimed |
| EP-3981401-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR PREVENTION OF DIABETES COMPRISING A CALCIUM CHANNEL BLOCKING AGENT AND AN INCRETIN MIMETIC | InSphero AG (CH) | 2022-04-13 | — | — | EP | claimed |
| EP-2649989-B1 | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof | UNIV KING SAUD (SA) | 2017-10-18 | — | — | EP | claimed |
| EP-2575473-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-01-20 | — | — | EP | claimed |
| EP-2649989-A1 | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof | King Saud University (SA) | 2013-10-16 | — | — | EP | claimed |
| EP-0412594-B1 | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists | MERCK & CO INC (US) | 1996-01-03 | — | — | EP | claimed |
| EP-0330924-B1 | Use of 1,4-dihydropyridine derivatives in the treatment of alcohol addiction | TROPONWERKE GMBH & CO KG (DE) | 1995-05-24 | — | — | EP | claimed |
| EP-0411766-B1 | Substituted quinazolinones as angiotensin II antagonists | MERCK & CO INC (US) | 1994-01-19 | — | — | EP | claimed |
| EP-0458823-B1 | A PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE POLYSUBSTITUTED 1,4-DIHYDROPYRIDINES | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1993-10-13 | — | — | EP | claimed |
| EP-0319983-B1 | ASSOCIATION OF PYRIMIDINE DERIVATIVES AND CALCIUM ANTAGONISTS TO INDUCE AND STIMULATE THE HAIR GROWTH AND TO REDUCE HAIR LOSS | L'OREAL (FR) | 1992-06-03 | — | — | EP | claimed |
| EP-0317780-B1 | SUSTAINED (CONTROLLED) RELEASE DELIVERY SYSTEM FOR SUBSTITUTED DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS | AMERICAN CYANAMID COMPANY (US) | 1992-05-20 | — | — | EP | claimed |
| EP-0237506-B1 | PHARMACEUTICAL COMPOSITION | LEJUS MEDICAL AKTIEBOLAG (SE) | 1991-08-14 | — | — | EP | claimed |
| EP-0293714-B1 | COMBINATIONS OF COMPOUNDS WITH ANTI-DEPRESSIVE ACTIVITY | Troponwerke GmbH & Co. KG (DE) | 1991-06-05 | — | — | EP | claimed |
| EP-0330924-A2 | Use of 1,4-dihydropyridine derivatives in the treatment of alcohol addiction | Troponwerke GmbH & Co. KG (DE) | 1989-09-06 | — | — | EP | claimed |
| US-4618598-A | Method of regulating hormone function or release | DUKE UNIVERSITY (US) | 1986-10-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | IAPP, SLC5A2, GLP1R | CACNA1F 11/4885CACNA1D 16/4885CACNA1S 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.